Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “buy” rating restated by analysts at Cowen and Company in a note issued to investors on Thursday.

Several other research firms have also recently commented on AERI. Needham & Company LLC reissued a “buy” rating and set a $65.00 target price on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. BidaskClub raised shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 target price on the stock in a research report on Monday, July 24th. Mizuho began coverage on shares of Aerie Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $62.00 target price (up previously from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $66.36.

Shares of Aerie Pharmaceuticals (AERI) traded down 3.30% during trading on Thursday, reaching $52.70. The company’s stock had a trading volume of 143,342 shares. The stock’s 50 day moving average price is $54.47 and its 200-day moving average price is $50.28. The firm’s market cap is $1.92 billion. Aerie Pharmaceuticals has a 12 month low of $32.05 and a 12 month high of $61.30.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. Equities analysts predict that Aerie Pharmaceuticals will post ($2.59) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/cowen-and-company-reiterates-outperform-rating-for-aerie-pharmaceuticals-inc-aeri/1609785.html.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Aerie Pharmaceuticals by 113,376.8% during the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after purchasing an additional 2,598,596 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Aerie Pharmaceuticals by 55.0% during the 2nd quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after purchasing an additional 766,300 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Aerie Pharmaceuticals by 64.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 436,955 shares of the company’s stock worth $22,962,000 after purchasing an additional 171,879 shares during the last quarter. Northern Trust Corp grew its stake in Aerie Pharmaceuticals by 6.6% in the 2nd quarter. Northern Trust Corp now owns 405,116 shares of the company’s stock valued at $21,289,000 after buying an additional 25,254 shares in the last quarter. Finally, Sectoral Asset Management Inc grew its stake in Aerie Pharmaceuticals by 3.4% in the 2nd quarter. Sectoral Asset Management Inc now owns 402,674 shares of the company’s stock valued at $21,161,000 after buying an additional 13,251 shares in the last quarter. Institutional investors own 94.64% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.